Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corporation develops oncolytic viral immunotherapies for cancer as a late clinical-stage immuno-oncology company. News about GNLX commonly centers on Olvi-Vec (olvimulogene nanivacirepvec), its proprietary modified vaccinia virus, and clinical development in platinum-resistant or refractory ovarian cancer, small cell lung cancer and non-small cell lung cancer.
Company updates also cover quarterly financial results, research and development spending, cash runway disclosures, equity financing activity, conference presentations and management changes tied to clinical development and medical strategy. Genelux has also disclosed an exclusive Greater China license for Olvi-Vec with Newsoara.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Genelux Corporation (NASDAQ: GNLX), a biopharmaceutical firm specializing in oncolytic viral immunotherapies, will ring the Nasdaq opening bell on March 29, 2023, to celebrate its recent IPO in January. CEO Thomas Zindrick expressed gratitude for stakeholder support as the company seeks to establish itself in the immunotherapy sector. The event will be broadcast live from the Nasdaq MarketSite Tower in New York City. Genelux's core product, Olvi-Vec, is a modified vaccinia virus designed to treat aggressive solid tumors, developed from the proprietary CHOICE™ platform. More details can be found at www.genelux.com.
Genelux Corporation has announced the pricing of its initial public offering (IPO) of 2,500,000 shares at $6.00 per share, totaling approximately $15.0 million in gross proceeds. The shares are set to trade on the Nasdaq under the ticker symbol GNLX, starting January 26, 2023, with the offering closing on January 30, 2023, pending customary conditions. The underwriters have a 30-day option to purchase an additional 375,000 shares. This capital will support Genelux's pipeline of oncolytic viral immunotherapies targeted at aggressive solid tumors, leveraging its proprietary CHOICE™ platform.